|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1995-12-12
|
|
pubmed:abstractText |
Chemotherapy induces high remission rates in high-grade lymphoma. However relapse remains a major problem. One approach to this is myeloablative chemotherapy with transplantation of autologous bone marrow or peripheral blood progenitor cells (PBPC). Immunological mechanisms have been suggested to play a role in the prevention of relapse after transplantation. We investigated the recovery of cellular immune functions after high-dose chemotherapy and PBPC transplantation in 5 patients with high grade non-Hodgkin's lymphoma. All patients showed rapid reconstitution of natural killer (NK) and inducible lymphokine-activated killer (LAK)-activity 10-14 days after transplantation. Four of 5 patients showed higher levels of LAK-generation in the post-transplant period compared with levels prior to myeloablative treatment. Absolute lymphocyte counts in peripheral blood reached 1.0 x 10(9)/l between days 10 and 13 with a predominance of CD8+ cells and an inversion of the CD4/CD8 ratio. Four of 5 patients had a transient increase in CD56+ and CD16+ cell counts post-transplant. No change in the proportion of CD25+ cells was noted. These results show that PBPC transplantation leads to a rapid recovery of cellular immune functions after myeloablative chemotherapy and provides evidence for an increased presence of LAK precursor cells early in the post-transplant period which can be activated by IL-2 to exert high levels of cytotoxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Busulfan,
http://linkedlifedata.com/resource/pubmed/chemical/Carmustine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/Mesna,
http://linkedlifedata.com/resource/pubmed/chemical/Podophyllotoxin,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
901-6
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7581089-Adolescent,
pubmed-meshheading:7581089-Adult,
pubmed-meshheading:7581089-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7581089-Bleomycin,
pubmed-meshheading:7581089-Bone Marrow Diseases,
pubmed-meshheading:7581089-Busulfan,
pubmed-meshheading:7581089-Carmustine,
pubmed-meshheading:7581089-Combined Modality Therapy,
pubmed-meshheading:7581089-Cyclophosphamide,
pubmed-meshheading:7581089-Cytarabine,
pubmed-meshheading:7581089-Doxorubicin,
pubmed-meshheading:7581089-Etoposide,
pubmed-meshheading:7581089-Female,
pubmed-meshheading:7581089-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:7581089-Humans,
pubmed-meshheading:7581089-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:7581089-Killer Cells, Natural,
pubmed-meshheading:7581089-Leukapheresis,
pubmed-meshheading:7581089-Lymphocyte Count,
pubmed-meshheading:7581089-Lymphocyte Subsets,
pubmed-meshheading:7581089-Lymphoma, B-Cell,
pubmed-meshheading:7581089-Lymphoma, Non-Hodgkin,
pubmed-meshheading:7581089-Male,
pubmed-meshheading:7581089-Melphalan,
pubmed-meshheading:7581089-Mesna,
pubmed-meshheading:7581089-Middle Aged,
pubmed-meshheading:7581089-Podophyllotoxin,
pubmed-meshheading:7581089-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:7581089-Time Factors,
pubmed-meshheading:7581089-Treatment Outcome,
pubmed-meshheading:7581089-Vincristine
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
CRC Department of Immunology, Paterson Institute for Cancer Research, Manchester, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
